

omissions were made to Figure 3: (1) one cluster of 10 nucleotides was inadvertently omitted from the thirteenth row of the first column of nucleotide clusters, and (2) the first nucleotide was inadvertently omitted each of the nucleotide clusters appearing in each row of the second through fifth columns.

Applicants herewith submit a corrected version of the figure, with the corrections marked in red on the attached version of the marked-up copy of the original Figure 3. Applicants assert that this amendment to Figure 3 is fully supported by the existing specification, because 1) the correct sequence of the mda-5 promoter depicted in Figure 3 was fully disclosed in the specifications, the Sequence Listings and the drawings of both International Patent Application PCT/US01/06960 and United States Patent Application Serial Number 09/515,363, the parent applications from which this continuation-in-part application claims priority, and 2) the full disclosure of these parent applications was incorporated into the instant application in their entireties by reference. Applicants therefore assert that this amended figure does not constitute new matter.


Applicants respectfully request that this petition be granted, and that the corrections to Figure 3 be entered and entitled to this application's filing date of January 22, 2002.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication to Deposit Account No. 02-4377. Two copies of this paper are enclosed.

A34614-A-PCT-USA-A (070050.1921)
PATENT

Respectfully submitted,

BAKER BOTTS L.L.P.

A handwritten signature in black ink, appearing to read 'Lisa B. Kole', written over a horizontal line.

Lisa B. Kole

Patent Office Reg. No. 35,225

Anthony Giaccio

Patent Office Reg. No. 39,684

Attorney for Applicants

(212) 408-2628

Enclosures

REPLACEMENT PARAGRAPHS SHOWING AMENDMENTS

Please replace paragraph [0029] on page 13 with the following paragraph:

[0029] FIGURE 4. Sequence alignment of putative RNA helicases. Clustal W alignment of helicase domains of putative RNA helicases that share the RNA helicase motifs with *mda-5*. Conserved residues in DExH group RNA helicase defined in Jankowsky and Jankowsky , 2000, *Nucleic Acids Res* 28:333-334, are aligned with consensus sequence (uppercase Roman numeric). Those underlined and marked with lowercase Roman numeric are for conserved motifs in this subgroup. Asterisks (*) = identical residues; colons (:) = conserved substitutions; dots (.) = semiconserved substitutions. MDA-5 (SEQ ID NO.:2); Q9HAM6 (SEQ ID NO.:12); RHIV-1 (SEQ ID NO.:13); RIG-1 (SEQ ID NO.:14); P34529 (SEQ ID NO.:15); Q9SP32 (SEQ ID NO.:16); Q09884 (SEQ ID NO.: 17).

Please replace paragraph [0075] on pages 31 and 32 with the following paragraph:

[0075] *mda-5* Expression Vectors. A hemagglutinin (HA)-tagged *mda-5* fragment was obtained by reverse transcription-PCR, using primers 5'-
[GCCACCATGTACCCATACGACGTCCCAGACTACGCTATGTCGAATGGGTATTCCA
CAGACG-3']/TCACTAATCCTCATCACTAAATAAACAGC;]_(SEQ ID NO:5) and 5'-
TCACTAATCCTCATCACTAAATAAACAGC-3' (SEQ ID NO.:10), and was cloned into the
EcoRV site of pcDEF3 with expression regulated by the EF-1 \forall promoter. An antisense *mda-5*
expression vector was constructed by cloning the EagI/SpeI *mda-5* genomic DNA (3.8-kbp)

fragment from a bacterial artificial chromosome clone into the SpeI/NotI site of pcDEF3. The genomic DNA fragment consists of the first exon and part of the first intron. A green fluorescent protein (GFP)-*mda-5* fusion expression vector was constructed by ligation of [a reverse transcription-PCR-derived] an *mda-5* cDNA product, derived by reverse transcription-PCR using the primers 5'-(G)ATGTCGAATGGGTATTCCACAGACG-3'(/TTTTTTTTTTTTCAGAGTAAAACAATC;]____(SEQ ID NO:6)_____and 5'-TTTTTTTTTTTTCAGAGTAAAACAATC-3' (SEQ ID NO.:11), into the S[m]maI site of pEGFP-C2 (CLONTECH).